Avidity Biosciences, INC Form 4 insider transactions

Avidity Biosciences Director Arthur A. Levin reported gifting 1,330 shares of common stock to a Donor Advised Fund.

Avidity Biosciences' Chief Technical Officer, Charles Calderaro III, increased his direct beneficial ownership by 13,524 shares following the vesting of performance-based restricted stock units and subsequent tax withholding on December 17, 2025.

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, acquired 27,500 shares of common stock through PSU vesting, while 13,695 shares were withheld for tax purposes.

Avidity Biosciences' Chief Commercial Officer, Eric Mosbrooker, acquired 72,000 shares through PSU vesting and subsequently sold shares to cover tax obligations.

Avidity Biosciences President and CEO Sarah Boyce reported the vesting of performance-based restricted stock units, tax-related share withholding, and a gift of shares.

Avidity Biosciences' Chief Legal Officer, John B. Moriarty, reported the future acquisition of 56,000 shares from PSU vesting and the disposition of 26,824 shares for tax withholding, effective December 17, 2025.

Avidity Biosciences' Chief Program Officer, Kathleen P. Gallagher, acquired 72,000 shares through PSU vesting and subsequently disposed of 41,366 shares for tax withholding purposes.

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, acquired 39,000 shares from PSU vesting and simultaneously sold 17,298 shares to cover tax obligations.

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, exercised stock options and subsequently sold 2,209 shares of common stock on October 22, 2025, under a pre-arranged 10b5-1 trading plan.

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, exercised options and sold 20,000 shares of common stock for a weighted-average price of $50.1529 per share.

Avidity Biosciences' Chief Commercial Officer, Eric Mosbrooker, exercised stock options and subsequently sold 6,562 shares of common stock for a weighted-average price of $45.3781 per share under a pre-arranged Rule 10b5-1 trading plan.

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, executed a pre-arranged transaction, exercising stock options and selling an equal number of common shares.

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, exercised stock options and sold 15,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, reported the exercise of stock options and subsequent sale of common stock totaling 1,542 shares under a pre-arranged 10b5-1 trading plan.

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, exercised stock options and subsequently sold 20,000 shares of common stock for a significant gain under a pre-arranged 10b5-1 trading plan.

Avidity Biosciences Director Troy Edward Wilson exercised options and sold company shares for a significant profit under a pre-arranged 10b5-1 trading plan.

Avidity Biosciences President and CEO, Sarah Boyce, exercised stock options and sold 50,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Avidity Biosciences' Chief Commercial Officer, Eric Mosbrooker, sold 6,563 shares of common stock for approximately $47.07 per share after exercising options.

Avidity Biosciences' Chief Program Officer, Kathleen P. Gallagher, sold 188 shares of common stock to cover tax withholding obligations related to RSU vesting.

Avidity Biosciences President and CEO, Sarah Boyce, exercised stock options and subsequently sold 25,000 shares of common stock as part of a pre-arranged 10b5-1 trading plan.

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, has reported planned stock option exercise and share sale under a 10b5-1 trading plan.

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, executed a pre-planned sale of 10,000 shares of common stock following an option exercise.

Avidity Biosciences' CFO, Michael F. MacLean, sold 30,914 shares of common stock for approximately $42.73 per share under a pre-arranged trading plan.

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, sold 1,542 shares of common stock for $46.66 per share, following the exercise of options, as part of a pre-arranged 10b5-1 trading plan.

Avidity Biosciences' Chief Commercial Officer, Eric Mosbrooker, exercised stock options and subsequently sold a significant number of shares.

Avidity Biosciences Director Troy Edward Wilson executed a pre-planned sale of company stock and exercised options, resulting in a net decrease in direct beneficial ownership.

Avidity Biosciences Director Arthur A. Levin exercised options and sold 107,500 shares of common stock under a pre-arranged trading plan.

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, sold over $3.48 million worth of company stock after exercising options, reducing his direct beneficial ownership.

Avidity Biosciences' Chief Legal Officer, John B. Moriarty, reported a future sale of 2,245 shares of common stock to cover tax withholding obligations related to RSU vesting.

Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, Inc., sold 911 shares of common stock for $30.24 per share on June 17, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.